Eukaryotic translation initiation factor 3B accelerates the progression of esophageal squamous cell carcinoma by activating β-catenin signaling pathway.

摘要: // Fengkai Xu 1, * , Cheng-Zhi 2, Jie Gu Xiaoming Liu 3 Ronghua Enyu Huang Yunfeng Yuan 1 Guangyin Zhao Jiahao Jiang Chen 4 Yiwei Chu Chunlai Lu Di Ge Department of Thoracic Surgery, Zhongshan Hospital, Fudan University, Shanghai, P. R. China 2 Otolaryngology, Shanghai Ninth People’s Jiao Tong University School Medicine, Immunology and Key Laboratory Medical Molecular Virology MOE/MOH, Basic Sciences, Pathology, These authors contributed equally to this work Correspondence to: Ge, email: gedi6902@hotmail.com Lu, lu.chunlai@zs-hospital.sh.cn Chu, yiwei_chu@126.com Keywords: esophageal squamous cell carcinoma, eukaryotic translation initiation factors 3B, β-catenin signaling pathway Received: October 22, 2015      Accepted: April 28, 2016      Published: May 30, 2016 ABSTRACT Introduction: Esophageal carcinoma (ESCC) is one the most aggressive malignant tumors. Eukaryotic 3B (EIF3B) considered influence tumor proliferation, invasion, apoptosis cycle, which act together promote progression However, role EIF3B in ESCC unknown. This study aims explore clinical biological ESCC. Results: expressions were up-regulated both tissues lines. Overexpression was associated with depth, lymph node metastasis advanced TNM stage. Importantly, patients high expression suffered shorter overall disease-free survival. Knockdown could inhibit proliferation apoptosis, interfere cycle vitro . EIF3B-knockdown cells form smaller subcutaneous tumors vivo Finally, we demonstrated activate pathway. Methods: Immunohistochemical staining Western blot performed detect patient The association between patients’ prognosis analyzed by Kaplan-Meier Cox regression. Then, CCK-8, colony-formation, Transwell wound-healing assay compare bio-functional change after knockdown EIF3B. Flow cytometry applied analyze induced knockdown. Tumor xenograft done verify in-vitro results. Conclusions: might serve as a novel marker for predicting potential therapeutic target, individually or other subunits EIF3 complex.